YTHDF1 and metabolic dysfunction-associated steatohepatitis: The silencing of YTHDF1 using lipid nanoparticles encapsulated with siYthdf1 (LNP-siYthdf1), in conjunction with anti-PD-1 therapy, synergistically inhibited MDSC recruitment and activated CD8 + T cell function in mouse models of NASH-HCC, thereby reducing tumor burden and growth [99].